Skip to main content
CAPR
NASDAQ Life Sciences

Capricor Q3 Loss Widens to $42.7M; Cash Down to $198.5M Ahead of Nov 22 PDUFA

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$8.905
Mkt Cap
$515.693M
52W Low
$2.96
52W High
$40.37
52W Position info
201% above low
Off High info
78% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

CAPR has more than doubled off its 52-week low of $2.96.

Summary

Capricor posted a $42.7 million third-quarter loss with cash down to $198.5 million from $318.1 million at year-end. Management says that funds at least twelve months of operations as the Deramiocel PDUFA date of November 22, 2026 approaches.


Key Events · Earnings and Guidance · CAPR

  • Q3 Loss Widens to $42.7M

    Net loss of approximately $42.7 million, or $0.73 per share, versus $24.6 million, or $0.54 per share, in the third quarter of 2025. Nine-month net loss reached $117.3 million.

  • Cash Falls to $198.5M

    Cash, cash equivalents, restricted cash and marketable securities totaled approximately $198.5 million at September 30, 2026, down from $318.1 million at December 31, 2025. No shares were sold under the ATM program from January 1 through November 10, 2026.

  • Spending Climbs on Launch Prep

    Third-quarter operating expenses rose to $44.7 million from $26.3 million a year earlier, driven by pre-commercial activities and manufacturing scale-up. A workforce reduction of about 10% was implemented in the quarter.

  • PDUFA Date Set for November 22, 2026

    The FDA classified the BLA amendment as a major amendment, extending review by three months to November 22, 2026. A July 2026 BIMO inspection produced a Form 483 with one observation, to which the company has responded.


Analysis · CAPR · Life Sciences

Capricor burned through roughly $120 million in nine months and now holds $198.5 million, which management says covers at least the next twelve months. The real swing factor, however, is the November 22, 2026 PDUFA date for Deramiocel. An approval brings the first revenue and a possible Priority Review Voucher; a rejection leaves a company spending about $45 million a quarter with no product and a distribution dispute heading to arbitration in mid-2027. The 10% workforce cut shows management is already tightening ahead of that binary outcome.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CAPR was trading at $8.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $515.7M. The 52-week trading range was $2.96 to $40.37. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CAPR - Latest Insights

CAPR
Nov 09, 2026, 9:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.08
Real-time Price: $8.91 info
Change: -$0.178 (-2%) info
Market Cap: $515.693M info
CAPR
Oct 05, 2026, 12:12 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $8.22
Real-time Price: $8.91 info
Change: +$0.685 (+8%) info
Market Cap: $515.693M info
CAPR
Sep 29, 2026, 9:24 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $10.27
Real-time Price: $8.91 info
Change: -$1.37 (-13%) info
Market Cap: $515.693M info
CAPR
Aug 24, 2026, 9:25 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.89
Real-time Price: $8.91 info
Change: +$2.01 (+29%) info
Market Cap: $515.693M info
CAPR
Aug 24, 2026, 9:25 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.89
Real-time Price: $8.91 info
Change: +$2.01 (+29%) info
Market Cap: $515.693M info